Stromal cells promote anti-estrogen resistance of breast cancer cells through an insulin-like growth factor binding protein 5 (IGFBP5)/B-cell leukemia/lymphoma 3 (Bcl-3) axis by Leyh, B. (Benjamin) et al.
Oncotarget39307www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 36
Stromal cells promote anti-estrogen resistance of breast cancer 
cells through an insulin-like growth factor binding protein 
5 (IGFBP5)/B-cell leukemia/lymphoma 3 (Bcl-3) axis
Benjamin Leyh1, Angela Dittmer1, Theresia Lange1, John W. M. Martens2, Jürgen 
Dittmer1
1Clinic for Gynecology, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany
2Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
Correspondence to:
Jürgen Dittmer, e-mail: juergen.dittmer@medizin.uni-halle.de
Keywords: stromal cells, anti-estrogen resistance, fulvestrant, mesenchymal stem cells, carcinoma-associated fibroblasts
Received: May 12, 2015     Accepted: October 09, 2015     Published: October 19, 2015
ABSTRACT
There is strong evidence that stromal cells promote drug resistance of cancer. 
Here, we show that mesenchymal stem cells (MSCs) and carcinoma-associated 
fibroblasts (CAFs) desensitize ERα-positive breast cancer cells to the anti-estrogen 
fulvestrant. In search for the mechanism, we found that MSCs and CAFs similarly 
increased the activity of the PI3K/AKT and the JAK/STAT3 pathways and upregulated 
the expression of integrin β1, IGF1R, HIF1α, CAIX and Bcl-3 in MCF-7 cells. Further 
analyses revealed that MSCs and CAFs coordinately induce these changes by 
triggering the downregulation of IGFBP5. Loss of IGFBP5 in MCF-7 cells was an 
early and long-lasting event in response to MSCs and CAFs and was accompanied 
by growth stimulation both in the absence and presence of fulvestrant. The growth-
stimulatory effect in the absence of fulvestrant could be attributed to PI3K/AKT 
pathway activation and could be mimicked by insulin. The growth-promoting effect 
in the presence of fulvestrant depended upon the upregulation of Bcl-3. By cRNA 
microarray analysis we identified additional IGFBP5 targets, of which two (KLHL4 and 
SEPP1) were inversely regulated by IGFBP5 and Bcl-3. BT474 cells also responded 
to stromal cells by downregulating IGFBP5 and upregulating the P-AKT, Bcl-3 and 
IGF1R levels, whereas T47D cells did not show any of these responses. In conclusion, 
our data suggest that, by targeting IGFBP5 expression in ERα-positive breast cancer 
cells, such as MCF-7 cells, MSCs and CAFs are able to orchestrate a variety of events, 
particularly activation of the PI3K/AKT pathway, upregulation of Bcl-3 expression 
and desensitization to anti-estrogen.
INTRODUCTION
Breast cancer is the most frequent cancer in 
women and the leading cause of cancer death in women 
world-wide [1]. As a heterogeneous disease breast 
cancer can be divided into subgroups either based 
on immunochemical or gene expression analysis [2]. 
Immunochemically, the ERα (estrogen receptor α)-positive 
breast cancer, the most common breast cancer subtype, can 
be distinguished from Her2 (human epidermal receptor 
2)-positive and triple negative breast cancers (negative for 
ERα, Her2 and progesterone receptor). ERα-positive breast 
cancers can selectively be treated with anti-estrogens or 
aromatase inhibitors (endocrine therapy). SERM (selective 
estrogen receptor modulator)-like anti-estrogens, such as 
tamoxifen, act by blocking ERα activity, SERDs (selective 
estrogen receptor downregulators), such as fulvestrant, 
additionally downregulate ERα expression. Aromatase 
inhibitors interfere with ERα activity by inhibiting 
estrogen synthesis, thereby causing estrogen deficiency. 
Anti-estrogens or aromatase inhibitors significantly reduce 
breast cancer mortality of patients suffering from ERα-
positive, but not ERα-negative breast cancer confirming 
the selectivity of these drugs [3]. The success of endocrine 
therapies, however, is limited by resistance to these 
drugs (endocrine resistance), either pre-existing (intrinsic 
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resistance) or developed in the course of treatment 
(acquired resistance) [4, 5].
Acquired resistance can be facilitated by the tumor 
stroma [6–8]. Both, extracellular matrix and stromal 
cells are able to protect cancer cells against drugs. The 
carcinoma-associated fibroblast (CAF), an important 
component of the tumor stroma and involved in tumor 
progression, plays a major role in the acquisition of drug 
resistance [9]. CAFs, a type of activated fibroblasts, can 
be generated from different cell types, among which is the 
mesenchymal stem cell (MSC) [10]. MSCs are commonly 
residing in the bone marrow and are attracted to wounds 
and cancer lesions [11, 12]. Once having entered a cancer 
lesion, they start interacting with the tumor cells, which 
most often leads to cancer progression. Like CAFs, 
MSCs have found to contribute to the acquisition of drug 
resistance [8, 13].
There are many mechanisms described that could 
lead to endocrine resistance [4, 5]. Often, this involves the 
activation of the survival pathway PI3K (phosphoinositol-
3-kinase)/AKT [14]. Also the activation of the Ras/Raf/
MEK1/ERK1/2 pathway can be protective against ERα-
directed drugs. The activation of either pathway can 
lead to phosphorylation of ERα, allowing ERα to act 
independently of estrogen. Both pathways are commonly 
activated through receptor tyrosine kinases (RTKs) 
[15]. Of the RTKs, IGF1R (insulin-like growth factor 1 
receptor) may be of particular importance for endocrine 
resistance, as it interacts with ERα [16] and its agonist 
IGF-1 (insulin-like growth factor 1) shares with ERα the 
ability to down-regulate critical growth repressor genes 
[17]. Regulation of IGF1R activity is complex and is not 
only controlled by its ligands IGF-1 and −2, but also by 
the IGF inhibitors IGFBP1-6 (IGF binding proteins 1–6) 
[15]. Interestingly, of these inhibitors, IGFBP2 has been 
shown to regulate ERα activity [18]. Of note, IGFBPs can 
also act in an IGF-independent manner [19]. E.g., IGFBP5 
has been reported to increase survival of MCF-7 cells in 
nutrient-poor conditions [20].
Besides RTKs, integrins, such as integrin β1, are 
typical activators of PI3K/AKT and Ras/Raf/MEK1/
ERK1/2 pathways [21] and have also been linked to 
endocrine resistance [8]. Also the NFκB (nuclear factor 
of κB) pathway, which interferes with ERα activity 
in multiple ways [22, 23], has been implicated in the 
acquisition of endocrine resistance [24, 25]. Specifically, 
Bcl-3 (B-cell leukemia/lymphoma 3), a member of the 
atypical IκB family and regulator of NFκB activity in the 
nucleus [26, 27], has been shown to promote proliferation 
of MCF-7 cells under estrogen deficiency [28]. Bcl-3 is 
also linked to breast cancer metastasis [29].
CAFs have been shown to induce resistance to 
the SERM tamoxifen by activating the PI3K/AKT and/
or Ras/Raf/MEK1/ERK1/2 pathways [30, 31], though 
other mechanisms have also been reported, which include 
synthesis of estrogen by CAFs [32] or secretion of ketone 
bodies and lactate by autophagic CAFs [33]. Little is 
known about the mechanisms by which MSCs induce 
resistance to ERα-targeting drugs. One report shows that 
higher expression of the progesterone receptor (PR) may 
be linked to the ability of MSCs to support growth of 
ERα-positive MCF-7 breast cancer cells under estrogen 
deficiency [34].
We explored the possibility that MSCs and CAFs 
may interfere with the SERD-like anti-estrogen fulvestrant 
(ICI 182,780), which also downregulates ERα protein 
levels. We found that either stromal cell type promoted 
growth of ERα-positive breast cancer cells, such as MCF-
7 cells, in the presence of fulvestrant. Searching for the 
underlying mechanism, we identified Bcl-3 as a major 
mediator of protection against fulvestrant and found that 
Bcl-3 was regulated by MSCs and CAFs along with other 
proteins and phospho-proteins in a coordinated manner 
through IGFBP5.
RESULTS
MSCs and CAFs promote resistance of MCF-7 
cells to the anti-estrogen fulvestrant
To show that the anti-estrogen fulvestrant interferes 
with the activity of MCF-7 breast cancer cells, we 
examined the effects of fulvestrant on cell growth, on the 
expression of selected proteins, on spheroid formation 
and on expression of mesenchymal and stem cell 
markers. The incubation of MCF-7 cells with fulvestrant 
at a final concentration of 100 nM for six days strongly 
reduced growth of individual clones in clonogenic assays 
(Figure 1A). Along with it, the protein expression of the 
proliferation marker Ki67 substantially decreased (Figure 
1B). Also, as expected, fulvestrant diminished the protein 
level of ERα (Figure 1B). Furthermore, fulvestrant 
downregulated P-AKT and P-ERK1/2 levels (Figure 1B) 
suggesting that fulvestrant exerts an inhibitory effect on 
the PI3K/AKT- and the Ras/Raf/MEK/ERK1/2 pathways. 
Fulvestrant also interfered with cell aggregation in 3D 
suspension cultures and led to the generation of smaller 
spheroids (Figure 1C). In addition, fulvestrant significantly 
induced the RNA expression of the mesenchymal proteins 
vimentin, fibronectin and ACTA2 (α-smooth muscle 
actin) und induced the expression of a couple of stem cell 
markers, such as PROCR, ABCG2 (ATP binding cassette 
subfamily G2) and ALDH3A1 (aldehyde dehydrogenase 
3 family, member A1) (Figure 1D) while reducing the 
expression of the stem cell marker CD44. This may 
suggest that fulvestrant promotes the expansion of a pool 
of cells of a more mesenchymal phenotype, which may be 
more resistant to fulvestrant.
Next, we studied the effects of MSCs and CAFs on 
MCF-7 growth in the presence and absence of fulvestrant. 
When MCF-7 cells were co-cultured with MSCs at a ratio 
of 10:1 for five days and compared to MCF-7 cells grown 
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Figure 1: MSCs and CAFs promote growth of MCF-7 cells in the presence of fulvestrant. Effect of 100 nM fulvestrant on 
A. colony size of MCF-7 cells in the clonogenic assays, B. expression of ERα, Ki67, P-ERK1/2 and P-AKT levels in Western blot analysis, 
C. spheroid formation and D. RNA expression of mesenchymal markers (ACTA, VIM, FN1) and stem cell markers (CD44, PROCR, 
ABCG2, ALDH3A1). E, F. Effects of MSCs, MSC-CM and CAF-CM on MCF-7 cell growth in the presence and absence of fulvestrant. 
Cell growth was either determined by measuring the sizes of individual clones in the clonogenic assay (E) or by the ATP-based growth assay 
(F). G, H. Effect of CAF-CM on (G) spheroid size in the presence and absence of fulvestrant and (H) on the RNA levels of mesenchymal 
and stem cell markers in the absence and presence of fulvestrant. In (A, E), the data of a representative experiment are shown, in (D, F–H), 
each bar represents the mean value ± S.D. of at least three independent experiments. Statistical analysis for the clonogenic assay was 
performed by the Wilcoxon test (A, E). Other statistical analyses were done by using the student’s t-test. ACTA = α-smooth muscle actin, 
VIM = vimentin, FN1 = fibronectin-1, ABCG2 = ATP binding cassette subfamily G2), ALDH3A1 (aldehyde dehydrogenase 3 family, 
member A1), NE/CE = nuclear/cytosolic protein extract, RLU = relative light units.
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alone, average colony size was significantly increased in 
the presence, but not in the absence of fulvestrant (Figure 
1E). Growing MCF-7 cells in growth medium that contains 
20% conditioned medium from MSCs (20% MSC-
CM) or from CAFs (20% CAF-CM) had similar strong 
promoting effects on the growth of individual colonies 
in the presence of fulvestrant (Figure 1E). Unlike MSCs, 
20% MSC-CM or 20% CAF-CM had also some moderate 
effects on colony growth in the absence of fulvestrant. In 
a different set of experiments with an ATP-based growth 
assay, cell growth was monitored after cells had been 
seeded at higher cell density that prevented the formation 
of individual colonies, but still left sufficient space for 
cell growth over a growth period of five days. Also under 
these conditions, CAF-CM was able to strongly increase 
cell growth in the presence of fulvestrant, but failed to 
promote growth or even reduced growth in the absence of 
fulvestrant (Figure 1F).
We next sought to analyze whether stromal cells also 
affect spheroid formation. We found that 20% CAF-
CM increases the size of spheroids both in the presence 
and absence of fulvestrant (Figure 1G). However, these 
effects did not seem to be the result of increased MCF-
7 cell growth. It rather seemed that CAF-CM causes the 
MCF-7 cells in the spheroids to be more loosely packed 
(Figure 1G) This may be the result of a reduced cell-cell 
contact as was found in spheroids that MCF-7 cells had 
formed in the presence of MSCs [35]. Next, we examined 
whether CAF-CM affected the expression of mesenchymal 
and stem cell markers. Of the selected markers, only 
fibronectin-1 showed increased RNA levels upon treatment 
with CAF-CM both in the presence and absence of 
fulvestrant (Figure 1H). In the absence of fulvestrant, also 
the expression of ALDH3A1 was increased by CAF-CM.
Collectively, these data suggest that MSCs and 
CAFs secrete certain factors that protect MCF-7 cells from 
the growth-inhibitory effect of fulvestrant. Since most of 
the selected mesenchymal and stem cell markers were not 
affected by CAF-CM, it is unlikely that the stroma cell-
induced protective effect against fulvestrant is mediated 
by an increase in the stem/progenitor cell pool of the 
MCF-7 cells.
MSC- and CAF-CM interfere with the activities 
of signaling pathways and the expression of 
proteins involved in drug resistance
To identify the mechanism that underlies the 
MSC/CAF-induced fulvestrant resistance, we examined 
the expression of a number of proteins, integrin β1, 
IGF1R and Bcl-3, and the activities of a number of 
signaling pathways, the PI3K/AKT-, the Ras/Raf/MEK1/
ERK1/2-pathways, the JAK2 (janus kinase 2)/STAT3 
(signal transducer and activator of transcription 3) and 
the hypoxia-regulated pathway. All these proteins and 
signaling pathways have been associated with drug 
resistance and/or deregulation of ERα activity [14, 16, 17, 
21, 28, 36, 37]. To study the activities of the four pathways 
we determined the phospho-protein levels of AKT, 
ERK1/2, STAT3 and the plasma-membrane level of the 
hypoxia-regulated protein CAIX (carbon anhydrase) [38] 
by Western blot analysis. To mimic potential effects on the 
PI3K/AKT- and the Ras/Raf/MEK1/ERK1/2- pathways 
by stromal cells we used insulin, shown to induce these 
pathways in MCF-7 cells [39]. To recapitulate potential 
stromal cell effects on the hypoxia-regulated pathway we 
used the hypoxia-mimetic agent CoCl2.
We found that a 3-day-incubation of MCF-7 cells 
with 20% MSC- or 20% CAF-CM similarly increased 
phosphorylation of AKT and STAT3, while having no 
effect on ERK1/2 phosphorylation (Figure 2A). Both 
CMs also increased plasma membrane abundance of 
CAIX. As shown with CAF-CM, also the level of CAIX-
regulator HIF1α (hypoxia inducible factor 1α) was 
raised (Figure 2B). This suggests that MSC- and CAF-
CM activate the PI3K/AKT-, the JAK2/STAT3- and the 
hypoxia-regulated pathway, whereas it had no effect on 
the Ras/Raf/MEK/ERK1/2 pathway. However, limiting 
the duration of incubation with CAF-CM to overnight 
led to an increase in the P-ERK1/2 levels (Supplementary 
Figure S1) suggesting that the activation of the Ras/Raf/
MEK/ERK1/2 pathway by stromal cell CM is temporary. 
MSC- and CAF-CM also increased the plasma membrane 
levels of IGF1R and integrin β1 and the nuclear protein 
level of Bcl-3 (Figure 2A). Of note, the two Bcl-3-specific 
protein bands likely correspond to a phosphorylated and 
the non-phosphorylated form of Bcl-3, of which both are 
able to regulate transcription [40]. Insulin could mimic 
the effect of MSC- and CAF-CM on P-AKT and integrin 
β1 (Figure 2A). Also, like stromal cell-CM, insulin 
induced a temporary increase in ERK1/2 phosphorylation 
(Supplementary Figure S1). However, unlike stromal cell-
CM, insulin did not modulate the levels of P-STAT3, Bcl-
3, IGF1R and CAIX (Figure 2A). The hypoxia-mimetic 
agent CoCl2, that strongly induced the expression of HIF1α 
protein und CAIX in MCF-7 cells (Figure 2B), shared 
with insulin the ability to increase the integrin β1 level 
and also, like insulin, had no effect on Bcl-3 expression 
(Figure 2C). However, unlike insulin, CoCl2 recapitulated 
the effect of MSC- and CAF-CM on CAIX, P-STAT3, 
IGF1R expression, while having no effect on P-AKT 
(Figure 2C). Consequently, when combined, insulin and 
CoCl2 could mimic most of the effects of MSC- and CAF-
CM. The only two tested stroma cell-responsive proteins 
whose expression remained unchanged in response to a 
combined treatment with insulin and CoCl2 were Bcl-3 
and IGF1R.
To test whether Bcl-3 and IGF1R expression are 
linked, we downregulated Bcl-3 by a Bcl-3-specific 
siRNA (siBcl3). In fact, siBcl3 attenuated the effect of 
CAF-CM on the expression of IGF1R and also on that 
of CAIX, while it strongly increased the integrin β1 level 
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Figure 2: MSC- and CAF-CM upregulate the activities of signaling pathways and expression of proteins relevant in 
the acquisition of drug resistance. Western blot analyses of the indicated proteins and phospho-proteins were performed after MCF-
7 cells were incubated with insulin, 100 μM CoCl2, insulin plus CoCl2 (ins./CoCl2), MSC- or CAF-CM and/or transfected with siBcl3, 
siSTAT3 or with the control siRNA siLuc. Depending on the cellular location of the protein or phospho-protein, either the cytosolic (CE), 
nuclear (NE) or plasma membrane (PM) extract was used for the analysis A–C, E. For the visualization of the HIF1α protein, whole 
cell extracts (WCE) were prepared by lysing cells in RIPA buffer B. To check for equal loading of plasma membrane proteins, proteins 
remaining in the gel after blotting were stained with Coomassie Blue (Coom.).
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(Figure 2D). This suggests that stromal cells induce the 
expression of IGF1R and also CAIX by upregulating the 
Bcl-3 level. Since STAT3 can regulate Bcl-3 expression 
in prostate cancer [41], we wondered whether STAT3 
and Bcl-3 expression are also linked in MCF-7 cells. 
However, knock-down of STAT3 by a STAT3-specific 
siRNA (siSTAT3) only slightly reduced CAF-CM-induced 
Bcl-3 expression and, with it, also weakly diminished the 
levels of IGF1R and CAIX (Figure 2E). Hence, activation 
of STAT3 by stromal cell CM is unlikely to be the major 
cause for CM-induced Bcl-3 expression, although it may 
contribute to it.
MSCs and CAFs coordinately modulate 
signaling pathways and protein expression by 
downregulating the IGFBP5 level
Next we analyzed the involvement of the IGF1R-
dependent signal pathway in the MSC- and CAF-
induced effects for two reasons. One, MSC- and CAF-
CM upregulated the IGF1R level along with the P-AKT 
level. Two, blockage of IGF1R-dependent signaling by 
the IGF1R-specific inhibitor PQ401 strongly reduced 
the phosphorylation status of AKT (Supplementary 
Figure S1). suggesting that IGF1R is a major driver of 
the PI3K/AKT pathway in MCF-7 cells. IGF1R activity 
is regulated by its activators IGF1 and 2 and by the IGF-
binding proteins IGFBP1-6 which regulate the activity of 
the IGFs. Besides their IGF-dependent activities, IGFBPs 
also show IGF-independent effects [19]. Therefore, in 
theory, by modulating IGFBP expression, stromal cells 
could modulate IGF-dependent and -independent effects 
at the same time. Hence, we analyzed whether CAF-CM is 
able to induce changes in the expression of any of the IGFs 
and the IGFBPs by quantitative RT-PCR. We also included 
IGFBP7 in our analysis, since IGFBP7 was shown to bind 
to IGF1R and to block its activation by IGFs [42]. When 
we incubated MCF-7 cells with increasing amounts of 
CAF-CM (1, 5 and 20%), the mRNA level of IGF2, which 
showed higher basal levels than IGF1 (data not shown), 
increased up to ~15-fold (Figure 3A). Of the IGFBPs, 
IGFBP5, 6 and 7 showed a dose-dependent decline in their 
expression in response to CAF-CM, whereas the level of 
IGFBP3 increased in the presence of CAF-CM (Figure 
3B). Of all IGFBPs, IGFBP5 was expressed at the highest 
basal level in MCF-7 cells, followed by IGFBP4 and 
IGFBP2 (data not shown). The other four IGFBPs were 
much less abundant with IGFBP1 showing the lowest 
(barely detectable) expression. Therefore, of all CAF-CM-
induced changes in IGFBP expression, the changes in the 
IGFBP5 levels should be most relevant for IGF1R activity. 
Hence, we focused our further analysis on IGFBP5. We 
found that the change in the IGFBP5 level by CAF-CM 
was an early event. Four hours of incubation of MCF-
7 cells with CAF-CM was sufficient to bring IGFBP5 
expression down to ~50% of its original level (Figure 3C). 
In addition, the suppressive effect of CAF-CM on IGFBP5 
levels was long-lasting.
To analyze whether downregulation of IGFBP5 is 
sufficient to induce the observed effects of MSCs and 
CAFs on MCF-7 cells, MCF-7 cells were treated with an 
IGFBP5-specific siRNA (siIGFBP5). siIGFBP5 decreased 
IGFBP5 levels by ~4-fold, which was comparable to the 
decline in IGFBP5 expression as observed in response to 
CAF-CM (Figure 4A). Of note, siSTAT3 had no effect on 
IGFBP5 expression suggesting that stromal cell-induced 
activation of the JAK2/STAT3 pathway is not responsible 
for the downregulation of the IGFBP5 level. A comparison 
of the effects of siIGFBP5 and CAF-CM revealed that 
siIGFBP5 was as effective as CAF-CM to upregulate 
the levels of P-AKT, Bcl-3 and CAIX (Figure 4B). In 
addition, siIGFBP5 slightly increased the levels of IGF1R 
and P-STAT3, whereas siIGFBP5 alone failed to modulate 
the expression of integrin β1. Interestingly, treatment of 
MCF-7 cells with both CAF-CM and siIGFBP5, which 
reduced IGFBP5 expression to ~7% of its original level 
(Figure 4A), generated the highest levels of Bcl-3, IGF1R, 
CAIX, integrin β1 and P-STAT3 (Figure 4B). These 
data suggest that stromal cells can induce most of the 
observed effects on signaling pathway activity and protein 
expression by simply downregulating IGFBP5 expression.
Bcl-3 is involved in stromal cell-induced 
fulvestrant resistance
The strong effect of siIGFBP5 on the Bcl-3 level 
prompted us to further analyze the link between IGFBP5 
and Bcl-3 expression. First, we wanted to confirm 
that MSCs also downregulate the IGFBP5 level while 
upregulating that of Bcl-3. For this, we used two MSC 
isolates and either co-cultured MSCs with MCF-7 cells 
in a ratio of 1:50 or added 20% MSC-CM to the MCF-7 
cells. Under all conditions, both MSC isolates significantly 
downregulated IGFBP5 RNA expression and, at the same 
time, upregulated the Bcl-3 RNA level (Figure 4C). We 
next compared IGFBP5 levels with those of Bcl-3 in 76 
RNA samples isolated from MCF-7 cells either treated 
with CAF-CM (closed circles, N = 32) or left untreated 
(open circles, N = 44). The data suggest an exponential, 
inverse correlation between the expression of both genes 
such that changes in IGFBP5 expression have the most 
profound effects on Bcl-3 expression when IGFBP5 levels 
are low (Figure 4D). The hypothesis that IGFBP5 and 
Bcl-3 expression are linked is further supported by the 
observation that CAF-CM modulated Bcl-3 mRNA and 
protein expression early (Figure 4E, 4F), just as seen with 
IGFBP5 (Figure 3C).
Having established that downregulation of IGFBP5 
allows MSCs and CAFs to coordinate a number of events, 
we explored the possibility that a decline in the IGFBP5 
level also affects colony growth of MCF-7 cells. By using 
siIGFBP5, we found that a decrease in IGFBP5 expression 
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Figure 3: CAF-CM induces the downregulation of IGFBP5 expression. A, B. RT-PCR analyses of RNA isolated from MCF-7 
cells after 2-day-exposure to 0, 1, 5 or 20% CAF-CM for the abundance of IGF-1/-2 specific mRNAs (A) and IGFBP1-7-specific mRNAs 
(B). C. Time-course study to measure changes in IGFBP4/5 mRNA levels in MCF-7 cells within 4–72 h after addition of 20% CAF-CM 
or no addition of CAF-CM.
Oncotarget39314www.impactjournals.com/oncotarget
Figure 4: Knock-down of IGFBP5 mimics most of the CAF-CM-induced effects on signaling pathways and protein 
expression. A. RT-PCR analysis of IGFBP5 mRNA levels in MCF-7 cells transfected with siIGFBP5, siSTAT3 or siLuc (control siRNA) 
followed by treatment with CAF-CM or no treatment. B. Western blot analyses of levels of stromal cell-regulated proteins and phospho-
proteins after treatment of MCF-7 cells with siIGFBP5 or siLuc in the presence or absence of CAF-CM (CE = cytosolic extract, NE = 
nuclear extract, PM = plasma membrane extract). To check for equal loading of plasma membrane proteins, proteins remaining in the gel 
after blotting were stained with Coomassie Blue (Coom.) C. Effects of two different human MSCs isolates on IGFBP5 and Bcl-3 levels 
in MCF-7 cells. Either MSCs were co-cultured with MCF-7 cells in a ratio of 1:50 or 20% MSC-CM was added to the MCF-7 cells.  
D. RT-PCR analyses of RNAs isolated from MCF-7 cells treated with CAF-CM (•) or from untreated MCF-7 cells (○) for IGFBP5 and 
Bcl-3 mRNA levels. E, F. Comparison of the Bcl-3 mRNA RNA (E) and protein (F) levels in the presence and absence of CAF-CM in 
a time course experiment. For each time point, the difference in Bcl-3 expression between control cells and CAF-CM-treated cells is 
statistically significant as determined by paired sample student’s t-test. In (A, D, F), each bar represents the mean value ± S.D. of at least 
three independent experiments.
Oncotarget39315www.impactjournals.com/oncotarget
resulted in an increase in average colony size both in the 
absence and presence of fulvestrant (Figure 5A). To check 
whether the PI3K/AKT pathway was responsible for 
these effects, we repeated the experiments with insulin. 
While insulin was able to significantly increase average 
colony growth in the absence of fulvestrant, it failed to 
do so in the presence of fulvestrant (Figure 5B). This 
suggests that the effect of siIGFBP5 on growth in the 
presence of fulvestrant was not caused by the activation 
of the PI3K/AKT pathway. Next, we tested whether Bcl-3 
may affect MCF-7 cell growth. Strikingly, siBcl-3 did not 
significantly alter cell growth in the absence of fulvestrant, 
Figure 5: Bcl-3 knock-down specifically interferes with MCF-7 growth in the presence of fulvestrant. A, C. Effect of 
siIGFBP5 (A), siBcl3 (C) and siLuc (A, C) on the size of individual colonies of MCF-7 cells in the clonogenic assay in the presence or 
absence of fulvestrant and in the presence or absence of CAF-CM. B. Clonogenic assays performed with insulin- or mock-treated MCF-7 
cells. Statistical analyses were carried out by using the Wilcoxon test.
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but selectively reduced growth in the presence of 
fulvestrant, most profoundly in the presence of CAF-CM 
(Figure 5C). This suggests that the increased expression of 
Bcl-3 caused by stromal cell-induced downregulation of 
IGFBP5 is at least partially responsible for stromal cell-
mediated fulvestrant resistance.
Downregulation of IGFBP5 has an impact on the 
expression of stromal cell-regulated genes
We next sought to identify stromal cell-regulated 
MCF-7 cell genes that are inversely regulated by IGFBP5 
and Bcl-3. For this reason, we performed two sets of 
independent cRNA microarray experiments comparing 
the transcripts of MCF-7/MSC co-cultures (ratio: 50 
to 1) with those in MCF-7 cells alone. The expression 
of a total of 253 mRNA species was changed by ≥2-fold 
in the presence of MSCs (Supplementary Table S2). Of 
these, 18 mRNA species showed reduced expression in 
the MCF-7/MSC co-cultures. The much higher number 
of upregulated RNA species could at least partly be 
explained by the presence of MSC-derived RNAs, such 
as PAI-1 (plasminogen activator inhibitor-1)-specific, 
ZEB-1 (zinc finger E-box binding homeobox 1)-specific 
or CD90-specific RNAs, that are strongly expressed 
in MSCs, but weakly or not expressed in MCF-7 cells 
(data not shown). For further analysis, we focussed on 
the RNAs that showed lower expression in the MCF-7/
MSC co-cultures, since, in theory, they should derive from 
MCF-7 cells. Of the 18 downregulated mRNA species, 17 
coded for known genes. For 13 of these 17 genes MSC-
dependent changes could be confirmed by Q-RT-PCR 
assays. Of these 13 genes, two genes (CDSN and CALCR) 
showed very low expression and were therefore excluded 
from further analysis. The remaining 11 genes are listed 
in Table 1. Nine of these genes were also downregulated 
in MCF-7/MSC co-cultures when cells were kept in 3D 
suspension cultures that led to spheroid formation. Ten 
of these genes showed also reduced expression in MCF-
7/MSC co-cultures when MSCs and MCF-7 cells were 
separated by a 0.4 μm filter that prevented direct cell-cell 
contact, but allowed paracrine effects. MSC-CM induced 
the level of nine of these genes, while CAF-CM reduced 
the expression of all eleven genes. Interestingly, most of 
these genes were also responsive to insulin and CoCl2.
Collectively, these data suggest that these eleven 
genes are regulated by MSCs and CAFs through soluble 
factors that these stromal cells secret, just as was found for 
the stroma cell-mediated regulation of IGFBP5 and Bcl-3.
Examining the expression of these genes in the 
presence of siIGFBP5 and siBcl3, we found that two 
genes (SEPP1 and KLHL4) were inversely regulated 
by siIGFBP5 and siBcl3. Like stromal cells, siIGFBP5 
significantly downregulated the expression of these two 
genes, while siBcl3 upregulated their levels. Moreover, 
the expression of KLHL4 and SEPP1 correlated well with 
that of IGFBP5 (Figure 6A, 6C) and showed an inverse 
correlation to that of Bcl-3 (Figure 6B, 6D). As a control 
we used KLK11. This stromal cell-regulated gene was 
neither affected by siIGFBP5 nor by siBcl-3 (Table 1). 
Nor did the expression of this gene show any correlation 
with the expression of IGFBP5 or Bcl-3 (Figure 6E, 6F).
These data suggest that two MSC/CAF-regulated 
genes, KLHL4 and SEPP1, are inversely regulated by 
IGFBP5 and Bcl-3.
Stromal cell-induced downregulation of IGFBP5 
in other breast cancer cells
We next examined whether stromal cells may be 
able to modulate signal pathway activities and protein 
expression also in other ERα-positive breast cancer cell 
lines (BT474 and T47D) in a similar way as in MCF-7 
cells and whether they may also affect cell growth in the 
presence of fulvestrant. As seen with MCF-7 cells, BT474 
cells responded to CAF-CM by a significant decrease in 
the IGFBP5 RNA expression and a significant rise in the 
Bcl-3 RNA level (Figure 7A). CAF-CM also increased 
Bcl-3 protein expression and upregulated the levels of the 
P-AKT and P-STAT3 (Figure 7B). However, in contrast to 
MCF-7 cells, BT474 cells failed to increase the expression 
of integrin β1 and IGF1R in response to CAF-CM. Of 
note, insulin also failed to increase the integrin β1 level 
in BT474 cells (data not shown). By being much higher in 
BT474 cells than in MCF-7 cells, the level of integrin β1 
may have already reached its maximum value in its basal 
state. It is also noteworthy that the CAIX protein could not 
be detected by Western blot analysis, even when cells were 
treated with CoCl2 (data not shown). In an ATP-based 
growth assay, CAF-CM significantly promoted BT474 
growth in the presence of fulvestrant, though the effect 
was less pronounced than that seen with MCF-7 cells. 
Importantly, no effect of CAF-CM could be observed on 
BT474 cell growth in the absence of this drug (Figure 7C). 
Of note, clonogenic assay could not be performed with 
BT474 cells, since BT474 cells did not survive when 
seeded at low density.
Collectively, these data indicate that BT474 cells 
behave similar to MCF-7 cells in terms of their responses 
to CAF-CM. Like MCF-7 cells, BT474 cells show higher 
growth activity in the presence of fulvestrant, lower 
expression of IGFBP5, higher levels of Bcl-3 and an 
increase in the PI3K/AKT pathway activity suggesting 
that CAF-CM induces these changes in both cell lines 
through the same mechanism.
In contrast to BT474 and MCF-7 cells, T47D cells 
were quite unresponsive to CAF-CM in terms of changes 
in protein expression and pathway activities (Figure 
7D, 7E). CAF-CM only increased the P-STAT3 levels 
in T47D cells (Figure 7E). Of note, Bcl-3 protein could 
not be detected (data not shown). To check whether the 
PI3K/AKT and HIF1α/CAIX pathways are functional in 
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Table 1: Relative expression of selected MSC/CAF-responsive genes in MCF-7 cells under different 
conditions
gene relative RNA expression*
MCF7/
MSC 
co-
culture 
50:1, (#)
MCF7/
MSC co-
culture 
10:1, 3D
MCF7/
MSC 
TW (0.4 
μm) 10:1
MSC-
CM 
20%
CAF-
CM 
20%
siIGFBP5 
vs. siLuc
siBcl3 
vs. siLuc
siSTAT3 
vs. siLuc
Insulin 
vs. mock
CoCl2 
vs. mock
KLHL4 0.35 ± 
0.19 (p = 
0.018)
0.06 ± 
0.01 (p = 
0.02)
0.14 ± 
0.03 (p = 
0.0026)
0.28 ± 
0.05 (p = 
0.0055)
0.26 ± 
0.08 (p = 
0.0033)
0.49 ± 
0.26 (p = 
0.036)
2.46 ± 
0.68 (p = 
0.022)
0.72 ± 
0.09 (p = 
0.0052)
0.50 ± 
0.04 (p = 
0.011)
0.59 ± 
0.11 (p = 
0.030)
SEPP1 0.39 ± 
0.20 (p = 
0.013)
0.14 ± 
0.02 (p = 
0.0034)
0.54 ± 
0.17 (p = 
0.050)
0.86 ± 
0.05 (p = 
0.3)
0.25 ± 
0.01 (p < 
0.0001)
0.55 ± 
0.11 (p = 
0.03)
2.66 ± 
0.32 (p = 
0.0018)
1.53 ± 
0.16 (p = 
0.027)
0.47 ± 
0.19 (p = 
0.0087)
0.31 ± 
0.06 (p = 
0.0015)
TMEM26 0.39 ± 
0.24 (p = 
0.0038)
0.53 ± 
0.10 (p = 
0.037)
0.24 ± 
0.16 (p = 
0.008)
0.38 ± 
0.15 (p = 
0.0026)
0.47 ± 
0.06 (p = 
0.0028)
0.56 ± 
0.15 (p = 
0.0086)
1.22 ± 
0.07 (p = 
0.16)
0.75 ± 
0.05 (p = 
0.0054)
0.83 ± 
0.19 (p = 
0.42)
0.48 ± 
0.16 (p = 
0.013)
TGFBR3 0.53 ± 
0.19 (p = 
0.024)
0.36 ± 
0.08 (p = 
0.044)
0.30 ± 
0.06 (p = 
0.0008)
0.35 ± 
0.07 (p = 
0.0012)
0.45 ± 
0.04 (p = 
0.011)
0.64 ± 
0.35 (p = 
0.19)
0.98 ± 
0.08 (p = 
0.83)
1.00 ± 
0.17 (p = 
1.00)
0.61 ± 
0.04 (p = 
0.034)
0.54 ± 
0.08 (p = 
0.013)
RAB30 0.52 ± 
0.22 (p = 
0.00012)
0.36 ± 
0.03 (p = 
0.008)
0.37 ± 
0.06 (p = 
0.0009)
0.74 ± 
0.09 (p = 
0.16)
0.28 ± 
0.05 (p = 
0.0024)
0.65 ± 
0.28 (p = 
0.12)
1.67 ± 
0.37 (p = 
0.055)
0.87 ± 
0.16 (p = 
0.52)
0.25 ± 
0.04 (p = 
0.002)
0.81 ± 
0.05 (p = 
0.013)
FGF18 0.45 ± 
0.25 (p = 
0.012)
0.33 ± 
0.02 (p < 
0.0001)
0.21 ± 
0.06 (p = 
0.0002)
0.40 ± 
0.09 (p = 
0.037)
0.35 ± 
0.06 (p = 
0.0054)
0.66 ± 
0.54 (p = 
0.35)
1.16 ± 
0.09 (p = 
0.20)
1.16 ± 
0.47 (p = 
0.47)
0.67 ± 
0.14 (p = 
0.075)
0.55 ± 
0.06 (p = 
0.0008)
KLK11 0.34 ± 
0.10 (p = 
0.0018)
0.07 ± 
0.02 (p = 
0.0071)
0.19 ± 
0.12 (p = 
0.0005)
0.22 ± 
0.04 (p = 
0.035)
0.16 ± 
0.01 (p = 
0.0012)
0.87 ± 
0.20 (p = 
0.20)
1.22 ± 
0.23 (p = 
0.22)
1.24 ± 
0.09 (p = 
0.015)
0.53 ± 
0.21 (p = 
0.041)
0.45 ± 
0.04 (p = 
0.0018)
UGT2B15 0.36 ± 
0.19 (p = 
0.0059)
0.13 ± 
0.06 (p = 
0.0067)
0.16 ± 
0.03 (p = 
0.0026)
0.34 ± 
0.09 (p = 
0.0013)
0.16 ± 
0.01 (p = 
0.00091)
0.89 ± 
0.15 (p = 
0.38)
3.60 ± 
0.28 (p = 
0.0004)
1.41 ± 
0.38 (p = 
0.17)
0.44 ± 
0.19 (p = 
0.020)
0.64 ± 
0.16 (p = 
0.025)
KIF12 0.60 ± 
0.17 (p = 
0.01)
0.24 ± 
0.09 (p = 
0.0016)
0.34 ± 
0.13 (p = 
0.011)
0.30 ± 
0.01 (p < 
0.0001)
0.31 ± 
0.03 (p = 
0.011)
0.99 ± 
0.51 (p = 
0.96)
0.55 ± 
0.09 (p = 
0.0034)
1.24 ± 
0.18 (p = 
0.15)
0.37 ± 
0.06 (p = 
0.015)
0.42 ± 
0.14 (p = 
0.019)
RAMP3 0.51 ± 
0.41 (p = 
0.021)
0.69 ± 
0.40 (p = 
0.27)
0.41 ± 
0.15 (p = 
0.001)
0.33 ± 
0.09 (p = 
0.023)
0.30 ± 
0.04 (p = 
0.0086)
0.32 ± 
0.24 (p = 
0.013)
0.59 ± 
0.10 (p = 
0.022)
0.64 ± 
0.09 (p = 
0.023)
0.39 ± 
0.06 (p = 
0.015)
0.37 ± 
0.07 (p = 
0.012)
YPEL-1 0.44 ± 
0.26 (p = 
0.018)
0.83 ± 
0.20 (p = 
0.4)
0.81 ± 
0.04 (p = 
0.17)
0.55 ± 
0.08 (p = 
0.06)
0.35 ± 
0.09 (p = 
0.028)
0.23 ± 
0.19 (p = 
0.010)
0.88 ± 
0.32 (p = 
0.61)
0.62 ± 
0.19 (p = 
0.25)
0.21 ± 
0.10 (p = 
0.015)
0.63 ± 
0.13 (p = 
0.082)
*expression relative to control condition as measured by Q-RT-PCR after 2 days of incubation. Statistically significant 
changes are marked in bold. Genes are ordered by the strength of their response to siIGFBP5. RAMP3 and YPEL-1 are 
listed separately, as their expression is not significantly changed in response to MSCs in 3D spheroid cultures.
(#)condition as used for cRNA microarray analysis. TW = transwell.
KLHL4 = kelch-like 4, SEPP1 = selenoprotein P. plasma 1, TMEM26 = transmembrane protein 26, TGFBR3 = transforming 
growth factor β receptor III, RAB30 = RAB30, member RAS oncogene family, FGF18 = fibroblast growth factor 1, KLK11 = 
kallikrein-related peptidase 1, UGT2B15 = UDP glucuronosyl transferase 2 family polypeptide B15, KIF12 = kinesin family 
member 12, RAMP3 = receptor (G protein-coupled) activity modifying protein 3, YPEL-1 = yippee-like 1
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Figure 6: KLHL4 and SEPP1 mRNA levels change along with the IGFBP5 mRNA level in a linear fashion. A–F. RT-
PCR analyses of RNA isolated from MCF-7 cells either exposed to CAF-CM (•) or left untreated (○). Levels of KLHL4-, SEPP1- and 
KLK11-specific mRNAs were either compared with the mRNA level of IGFBP5 (A, C, E) or with the mRNA level of Bcl-3 (B, D, F). 
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Figure 7: BT474, but not T47D cells respond to CAF-CM by changing IGFBP5 and Bcl-3 levels and by increasing 
growth activity in the presence of fulvestrant. A–D. After BT474 cells (A, B) or T47D cells (D, E.) were treated with CAF-CM 
or left untreated for three days, RNA or proteins were isolated and analyzed for IGFBP5 and Bcl-3 RNA levels (A, D) or levels of certain 
proteins as indicated (B, E), respectively. To check for equal loading of plasma membrane proteins, blots were reprobed with an E-cadherin 
-specific antibody (α-E-cadh.). F. T47D cells were also tested for AKT phosphorylation and CAIX expression after 3-day-treatment with 
insulin or CoCl2, respectively. (C, G, H.) Effect of CAF-CM on BT474 and T47D cell growth in the presence or absence of fulvestrant as 
measured either by an ATP based assay (C, G) or by measuring the sizes of single colonies (H). In (A, C, D, G), each bar represents the 
mean value ± S.D. of at least three independent experiments, in (H), the data of a representative experiment are shown. Statistical analysis 
was either performed by using the student’s t-test (A, C, D, G) or the Wilcoxon test (H).
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T47D cells, we treated these cells with insulin and CoCl2. 
Insulin and CoCl2 were able to raise the P-AKT level or 
CAIX level, respectively, (Figure 7F) demonstrating that 
the failure of CAF-CM to induce insulin- and CoCl2-like 
effects in T47D cells was not due to unresponsiveness of 
the PI3K/AKT and HIF1α/CAIX pathways. In ATP- and 
colony growth assays, CAF-CM showed a promoting 
effect on T47D cell growth irrespective of whether 
fulvestrant was present or not (Figure 7G, 7H).
The data obtained with T47D cells suggest that the 
responses of ERα-positive breast cancer cells to stromal 
cells can differ.
The expression of Bcl-3 is associated with 
an unfavorable outcome of endocrinally treated 
breast cancer patients with ERα/ 
PR-positive tumors
We next sought to analyze whether Bcl-3 is 
associated with the outcome of breast cancer patients 
that suffered from ERα/PR-positive tumors and received 
endocrine treatment. For this reason, we performed an 
in-silico analysis by using the Kaplan-Meier-Plotter 
available under http://kmplot.com/analysis/index.
php?p=service&default=true which is based on data 
published by Gyorffy et al. [43]. The selected criteria 
(ERα+/PR+/received endocrine treatment) were met by 
a cohort of 229 patients. The analysis for this cohort 
revealed that higher Bcl-3 mRNA levels were significantly 
associated with a more unfavorable relapse-free survival 
(Figure 8A). We also run the analysis for KLHL4 and 
SEPP1, whose expression could be increased by siBcl-3 
and showed an inverse correlation to that of Bcl-3. For 
these two genes, higher mRNA levels correlated with 
a better relapse-free survival (Figure 8B, 8C). While 
the data for KLHL4 slightly missed the significance 
level (p = 0.051) (Figure 8B), those for SEPP1 were 
highly significant (Figure 8C). Collectively, these data 
are consistent with the notion that Bcl-3 is involved in 
endocrine resistance and that KLHL4 and SEPP1 are 
negatively regulated by Bcl-3. The data might also suggest 
that Bcl-3 mediates endocrine resistance at least partially 
by downregulating KLHL4 and SEPP1.
DISCUSSION
The data presented here show that MSCs and CAFs 
affect ERα-positive breast cancer cells in a similar way. 
They promote cellular growth in the presence of the 
anti-estrogen fulvestrant and change the activities of 
the same signaling pathways and the expression of the 
same proteins. Most of the changes in signaling pathway 
activities and protein expression could be recapitulated 
by combined treatment with insulin and CoCl2. Only 
stromal cell-induced changes in IGF1R and Bcl-3 
expression could not be mimicked by a combination 
of these agents. We present evidence that stromal cells 
induce all of these changes by downregulating IGFBP5 
expression. Downregulation of IGFBP5 also contributed 
to the activation of STAT3. It seems therefore that, by 
downregulating IGFBP5, MSCs and CAFs coordinately 
induce a wide range of changes in breast cancer cells.
Since some changes as induced by IGFBP5 
downregulation could be mimicked by insulin, some by 
CoCl2 and others neither by insulin nor CoCl2, it is likely 
that IGFBP5 fulfills several different functions in breast 
cancer cells. Besides its classical function as a regulator 
of IGF-dependent IGF1R activation [44], IGF1R-
independent actions of IGFBP5 have been described [19]. 
E.g., it has been shown that, by binding to integrin α2/
β1, IGFBP5 is able to regulate cell adhesion, migration 
and survival of MCF-7 cells [20]. This activity did not 
require the N-terminal domain, which is responsible for 
its IGF1R-depending action, but the C-terminal domain, 
which interacts with heparin. The notion that the N- and 
C-terminal domains of IGFBP5 have different functions is 
also supported by a study that showed that the N-terminal 
domain blocks proliferation of osteosarcoma cells and 
induces apoptosis, whereas the C-terminal domain inhibits 
migration and invasion [45]. In addition, the C-terminal 
domain contains a nuclear localization sequence allowing 
IGFBP5 to fulfill functions in the nucleus [46]. IGF1R-
independent functions of IGFBP5 have also been found in-
vivo studies [47] just further substantiating the hypothesis 
that at least two independent activities of IGFBP5 exist.
Downregulation of IGFBP5 by siIGFBP5 resulted in 
increased cellular growth both in the presence and absence 
of fulvestrant. The effect of siIGFBP5 on cell growth in 
the absence of fulvestrant could be mediated by its insulin-
like effect on P-AKT, since insulin was able to foster cell 
growth in absence, but not in the presence of fulvestrant. 
The effect of siIGFBP5 on cell growth in the presence of 
fulvestrant is likely mediated by upregulation of Bcl-3 
expression, since siBcl-3 specifically attenuated cellular 
growth in the presence of fulvestrant, while showing 
no effect on growth in its absence. Hence, Bcl-3 may 
protect ERα-positive breast cancer cells, such as MCF-7 
cells, against fulvestrant. In line with this hypothesis, a 
previous study on MCF-7 cells grown in ovariectomized 
mice showed that estrogen deficiency was linked to higher 
Bcl-3 expression [28]. In this study, along with the higher 
expression of Bcl-3, a higher DNA-binding activity of 
NFκB was observed. By binding to p50/p50 and p52/
p52 NFκB homodimers, Bcl-3 is thought to increase 
NFκB activity [27]. Thus, by upregulating Bcl-3 levels in 
ERα-positive breast cancer cells, MSCs and CAFs may 
pave the way towards an NFκB-dependent growth under 
conditions where ERα is not functional. Interestingly, 
NFκB activation does not only protect against loss of 
ERα function, but also promotes growth of Her2-positive 
breast cancer cells in the presence of a Her2 inhibitor [48] 
suggesting that NFκB activation is a general option for 
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Figure 8: Higher Bcl-3 expression is associated with an unfavorable prognosis of endocrinally treated breast cancer 
patients with ERα+/PR+-tumors. In silico-Kaplan-Meier-Plotter analysis of 229 endocrinally treated breast cancer patients with 
ERα+/PR+-tumors for an association of outcome (relapse-free survival) with Bcl-3 A. KLHL4 B. or SEPP1 C. expression by choosing best 
cut-off.
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breast cancer cells to survive under conditions where the 
major growth-permitting pathway is blocked. In line with 
this notion, ERα-negative breast cancer cells are found to 
be more dependent on NFκB activity for proliferation than 
ERα-positive cells [49].
We could show that stromal cell-induced 
downregulation of IGFBP5 expression and concomitant 
upregulation of Bcl-3, IGF1R and P-AKT levels is not 
only seen with MCF-7 cells, but also with BT474 cells. 
This suggests that the observed changes as inflicted by 
stromal cells are not limited to a specific cell line, but 
of greater importance. On the other hand, the failure of 
T47D cells to react this way upon exposure to stromal 
cells indicates that breast cancer cells do not necessarily 
respond to stromal cells by inducing changes in IGFBP5 
and Bcl-3 expression. T47D cells expressed Bcl-3 protein 
at non-detectable level as judged by Western blot analysis. 
Hence, it is unlikely that Bcl-3 is involved in fulvestrant 
resistance developed by T47D cells. In agreement with 
this notion, recent data showed that T47D cells activate 
Aurora kinase B to gain fulvestrant resistance [50].
How stromal cells downregulate IGFBP5 expression 
in breast cancer cells has still to be determined. IGFBP5 
expression has been reported to be positively regulated 
by STAT3 in fibroblasts [51]. However, we did not find 
an effect of siSTAT3 on the IGFBP5 level in MCF-7 
cells (Figure 4A). Nor did siSTAT3 prevent the stromal 
cell-induced effects on signaling pathways and protein 
expression (Figure 2E). Hence, interleukin-6, the major 
stromal-cell secreted stimulator of STAT3 activity 
[52, 53], is unlikely to be responsible for IGFBP5 
downregulation and its consequences. We also tested 
SDF-1 (stromal cell derived factor-1) and other cytokines, 
known to be secreted by stromal cells, for their ability 
to downregulate IGFBP5, but so far we did not see any 
effect. MSCs and CAFs also secret high amounts of PAI-
1 (plasminogen activator inhibitor-1) (data not shown). 
This protease inhibitor has several functions, including 
a critical role in migration [54], which links this protein 
to cancer progression [55]. To analyze its importance 
for the stromal cell-induced effects, we eliminated PAI-
1 from CAF-CM by transfecting CAFs with a PAI-1-
specific siRNA, but did not find any evidence that this 
treatment changes the ability of CAF-CM to induce 
IGFBP5 downregulation in MCF-7 cells (data not shown). 
Besides secreted proteins, microvesicles (exosomes and 
shedding vesicles) as released by MSCs and CAFs [56, 
57], might be responsible for the induction of IGFBP5 
downregulation. In terms of shedding vesicles, we could 
confirm that they are released by MSCs (data not shown). 
We are currently studying their potential role in stromal 
cell-induced IGFBP5 downregulation.
By a comparative gene expression analysis of 
MCF-7 cells grown alone or in the presence of MSCs 
we identified a number of genes whose expression is 
downregulated in response to MSCs and CAFs. The 
levels of approximately half of these genes were also 
decreased by siIGFBP5. Of these genes, KLHL4 and 
SEPP1 were upregulated by siBcl3. The expression of 
these two genes changed along with the level of IGFBP5 
in a linear fashion and inversely along with that of Bcl3. 
This suggests that KLHL4 and SEPP1 can be regulated 
through the IGFBP5/Bcl-3 axis. Interestingly, treatment of 
MCF-7 cells with TNFα, which stimulates NFκB activity, 
was found to downregulate SEPP1 [58] suggesting that 
SEPP1 is an NFκB/Bcl-3 target at least in MCF-7 cells. 
However, since downregulation of SEPP1 expression 
could also be induced by insulin and CoCl2, NFκB/Bcl-
3 may act in concert with HIF1α and the PI3K/AKT 
pathway, all activated by stromal cell-induced IGFBP5 
downregulation. One way by which the PI3K/AKT 
pathway could downregulate SEPP1 expression is by 
inhibiting the activity of the forkhead box transcription 
factor FoxO1A [59–61], a tumor suppressor protein shown 
to activate SEPP1 transcription in hepatoma cells [59]. 
Interestingly, in in-silico survival analysis, we found a 
correlation of higher Bcl-3 expression and lower KLHL4 
and SEPP1 expression with unfavorable outcome of 
endocrinally treated breast cancer patients that suffered 
from a ERα+/PR+-tumor suggesting that not only Bcl-3 
is linked to endocrine resistance, but also its target genes 
KLHL4 and SEPP1.
In conclusion, our results suggest that MSCs and 
CAFs are able to trigger downregulation of IGFBP5 
expression in ERα-positive breast cancer cells, such as 
MCF-7 cells, and, as a consequence, induce a number 
of changes in signaling pathway activities and gene 
expression (summarized in Figure 9). One of these 
changes, the upregulation of Bcl-3 expression, is at least 
partly responsible for the promoting effect of MSCs and 
CAFs on the cellular growth in the presence of fulvestrant. 
Our data also show that, even within the subgroup of 
ERα-positive breast cancer, cancer cells may or may not 
respond to MSCs and CAFs by downregulating IGFBP5 
expression indicating that ERα-positive breast cancers are 
a heterogeneous group also in respect to their interactions 
with stromal cells.
Since Bcl-3 expression could be linked to 
unfavorable prognosis of breast cancer patients that 
received endocrine treatment, Bcl-3 may be a suitable 
biomarker for predicting endocrine therapy response of 
patients with ERα-/PR-positive breast cancers.
MATERIALS AND METHODS
Cell culture
MCF-7, BT474 and T47D breast cancer cells, whose 
identities were confirmed by authentication (LGC standards, 
Wesel, Germany or Genolytic, Leipzig, Germany), and 
immortalized 19TT breast CAFs [62, 63] were maintained 
in RPMI medium supplemented with 10% fetal calf serum 
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(FCS, Pan Biotech) in the absence of antibiotics. Human 
MSCs were kindly provided by J. Lützkendorf and L. 
Müller. MSCs were isolated from human bone marrow and 
propagated as described [35]. Breast cancer cell lines and 
stromal cells were maintained in the same batch of serum. 
To obtain conditioned medium (CM) from CAFs (CAF-
CM), cells were kept at 100% confluency for three days. 
For MSC-CM, MSCs were kept at ~50% confluency for 
three days (to prevent differentiation). To remove floating 
cells and debris, CMs were centrifuged at 3000 rpm in 
a Multifuge 3 (Heraeus) for 10 minutes. Unless stated 
otherwise, for treatment with stromal cell CM, MSC- or 
CAF-CM was mixed with growth medium 1+4, referred as 
20% MSC-CM or 20% CAF-CM, respectively. Cells were 
incubated with CM for 3 days. Co-culture experiments 
were performed by mixing MCF-7 cells with MSCs in a 
ratio of 10:1 or 50:1. In transwell experiments, MSCs were 
separated from MCF-7 cells by a 0.4 μm pore membrane 
(Greiner) with the MCF-7 cells grown on the bottom of the 
well of a 6-well-plate and the MSCs attached to the upper 
side of the membrane. Spheroid assays were performed 
as described [35]. Based on data reported by Kirkegaard 
Figure 9: Proposed mechanism of stromal cell induced fulvestrant resistance. Factor(s) secreted by MSCs and CAFs lead to 
a decline in the IGFBP5 expression. The reduced IGFBP5 level results in the release of IGFs from the IGF/IGFBP5 complex allowing IGF 
to activate IGF1R, thereby activating the PI3K/AKT signaling pathway. Besides blocking IGF activity by this IGF-dependent function, 
IGFBP5 also shows IGF-independent actions (e.g. as an intracellular protein). Through this IGF-independent action IGFBP5 likely keeps 
Bcl-3 expression down. Consequently, when stromal cells downregulate IGFBP5 expression the Bcl-3 expression raises. This leads to 
fulvestrant resistance and to changes in the expression of the Bcl-3 target genes IGF1R , KLHL4 and SEPP1.
Oncotarget39324www.impactjournals.com/oncotarget
et al. [64] cell were incubated with fulvestrant at a final 
concentrations of 100 nM. Insulin, PQ401 and CoCl2 were 
added to cells at a final concentration of 8 μg/ml (~90 μIU/
ml, as determined by insulin ELISA, Hölzel Diagnostika), 
10 μM and 100 μM, respectively.
For spheroid formation in 3D suspension cultures, 
cells were incubated on a layer of 2% Seakem GTG 
agarose (dissolved in PBS) in 96-well plates at a density 
of 5 × 103 cells/well for 3–4 days in the presence of 
fulvestrant and/or CAF-CM or in the absence of both 
agents. To measure the spheroid size, a picture was taken 
by an AxioCam MRc 5 camera and the area displayed on 
this picture measured by AxioVision R 4.5 software as 
described previously [65].
Antibodies and reagents
For Western blot analysis, the following antibodies 
were used (working dilutions are given in brackets). 
Rabbit polyclonal antibodies: anti-P(S473)-AKT (1:2000, 
D9E, Cell Signaling), anti-Bcl-3 (1:1000, C-14, Santa 
Cruz), anti-P(Thr202, Tyr204)-ERK1/2 and anti-ERK1/2 
(both 1:2000, Cell Signaling), anti-ERα (1:2000, Santa 
Cruz, HC-20), anti-IGF1Rβ (1:2000, Cell Signaling), 
anti-P(Tyr705)-STAT3 (1:1000, D3A7, Cell Signaling) 
and anti-STAT3 (1:1000, 79D7, Cell Signaling); rabbit 
monoclonal antibodies: anti-integrin β1 (1:2000, 
EPR1040Y, Abcam), anti-GAPDH (1:5000, Ambion) 
and Ki67 (1: 2000, Epitomics, clone EPR3610); mouse 
monoclonal antibodies: anti-(pan)AKT (1:1000, 40D4, 
Cell Signaling), anti-E-cadherin (1:5000, BD Transduction 
Lab.) and anti-HIF1α (1:1000, BD Transduction Lab.). 
Anti-CAIX was kindly provided by S. Pastorekova. 
Secondary antibody conjugates (anti-rabbit/anti-mouse 
horse radish peroxidase, 1:2000) were purchased from 
Cell Signaling.
Fulvestrant (LKT Laboratories) was purchased from 
Biomol (Hamburg/Germany), PQ404 from Calbiochem 
and recombinant human insulin was from Sigma-Aldrich.
RNA interference
Small interference (si)RNAs were purchased 
from Eurofins MWG. Transfection was performed by 
electroporation as described [66]. Briefly, cells were 
trypsinized, washed once in RPMI medium, electroporated 
by using a Bio-Rad GenePulserX-Cell at 250 V and 800 μF 
and kept on ice for 30 min. Cells were then transferred 
to a 6 or 10 cm (Æ) culture dish and incubated for two 
days to allow the siRNA to downregulate the expression 
of its target. The effect of the siRNA was confirmed by 
Western blot and/or Q-RT-PCR analysis. The following 
siRNAs (sense-strand) were used: siBcl3 (5′-UGG UCU 
UCU CUC CGC AUC A-3′), siLuc (5′-CUU ACG CUG 
AGU ACU UCG A-3′), siIGFBP5 (5′-GCA GAU CUG 
UGA AUA UGA A-3′) and siSTAT3 (5′-GAA UCA CGC 
CUU CUA CAG A-3′).
Growth assays
To determine cell growth of individual clones, 
cells were trypsinized, counted and seeded on a 10 cm 
(Æ) petri dish (3 × 104 cells per dish) in 10 ml growth 
medium. Cells were then incubated with MSC-CM, 
CAF-CM or insulin and/or fulvestrant or left untreated 
for five days. Cell growth of individual clones were 
determined by measuring the size of each clone by using 
an AxioCAM MRc5 camera and the AxioVision R 4.5 
imaging software (Zeiss). Single cells were not counted. 
For each condition, at least fifty individual clones were 
randomly chosen and measured. In RNA interference 
experiments, cells were transfected with siRNA and 
incubated for two days before the clonogenic assay was 
started.
To examine cell growth activity at higher cell 
density an ATP-based assay (Vialight Plus Kit, Lonza) 
was used. Cells were seeded at a density of 1 × 104 or 3 
× 104 per well of a 24-well plate and incubated for 5 to 7 
days in the presence of fulvestrant and/or CAF-CM or in 
the absence of both. After removal of the growth medium, 
cells were washed once with PBS and lysed by adding a 
mixture of 100 μl PBS and 50 μl lysis buffer. Cell lysates 
were cleared by microfugation at 4000 rpm for 5 min. 
After 75 μl of the cleared lysate was mixed with 50 μl 
luciferase stock solution, the mixture was incubated for 
2 min at RT and luciferase activity measured in a Sirius 
luminometer (Berthold).
Quantitative RT-PCR
RNA isolation, cDNA synthesis and quantitative 
(Q) PCR were carried out as described [66], except 
that the RNA isolation kit was from Roche and the 
dNTP mix was from Qiagen. Briefly, cDNA synthesis 
was done by using Superscript II (Invitrogen) by 
starting from 1 μg total RNA. For Q-PCR, ABsolute 
QPCR SYBR Green Fluorescein Mix (Thermo Fisher 
Scientific Biosciences) was used. PCRs were run in a 
BioRAD iCycler. Results were analyzed by iQ5 Optical 
System software version 2.1. Relative RNA levels of 
genes were calculated by the comparative Ct (2−∆∆Ct) 
method by using GAPDH and HPRT as reference genes 
for normalization. The primers used for Q-PCR are 
listed in Supplementary Table S1.
cRNA microarray analysis
In two independent experiments, 5 × 105 MCF-7 
cells were seeded into the well of a 6-well plate alone 
or together with 1 × 104 MSCs and grown for two days 
before total RNA was isolated. After the RNA was quality-
checked by an Agilent 2100 Bioanalyzer, gene expression 
analyses were performed by Miltenyi Biotec by using 
Agilent Whole Human Genome Oligo Microarrays 
8 × 60K. Briefly, cRNAs were generated from 100 ng 
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of each RNA sample by the Agilent Low Input Quick 
AMP labeling kit (Agilent Technologies). RNAs from 
control samples (MCF-7 alone) were labeled with Cy3, 
those from MCF-7/MSC co-culture samples with Cy5. 
Of the corresponding Cy3- and Cy5-labeled fragmented 
cRNAs, 300 ng each were combined and hybridized o/n 
to the oligo microarray by following the instructions of 
the manufacturer (Agilent Technologies). Imaging and 
data analysis was carried out by using Agilent Feature 
Extraction Software.
Protein extraction and western blot analysis
Protein extractions from the membraneous, 
cytosolic and nuclear fractions and Western blot analysis 
were carried out as described [66]. Briefly, after having 
been scraped off the plate, cells were centrifuged and 
resuspended in 400 μl buffer A (10 mM HEPES (pH 
7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA) and 
passed through a 20-gauge needle. Stepwise centrifugation 
at 3000, 6500 and 13000 rpm in a microfuge was used 
to obtain cytosolic, nuclear and membraneous protein 
fractions. For nuclear or membraneous protein extraction, 
the pellet was extracted in buffer C (20 mM HEPES 
(pH 7.9), 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1 mM DTT) or buffer D (5 mM HEPES (pH 7.9), 0.5 mM 
K-EDTA (pH 7.2), 1 mM DTT), respectively. For HIF1α 
detection, whole cell extracts (WCE) were prepared as 
described [67]. Briefly, depending on cell density, cell 
layers were incubated with 100–300 μl ice-cold RIPA 
lysis buffer (50 mM Tris HCl (pH 7.4), 200 mM NaCl, 
1 mM EDTA, 1 mM EGTA, 1% TritonX-100, 0.25% 
deoxycholate) containing a protease inhibitor cocktail 
(1:100) (Sigma-Aldrich, P8340) for 20 min and scraped 
off from the plate. Lysates were cleared by microfugation 
at full speed for 10 min.
Ten μg protein of each sample was separated on a 
10% SDS-polyacrylamide gel and transferred to a PVDF 
membrane (Millipore). After blocking the membrane in 
2% skim milk (Applichem) dissolved in washing buffer 
(10 mM Tris/HCl (pH 7.5), 100 mM NaCl, 1 mM EDTA), 
it was sequentially incubated with the primary antibody 
and the secondary antibody in washing buffer containing 
0.2% skim milk. Peroxidase activity was visualized by 
chemoluminescence using ECLPlus and Hyperfilm ECL 
(GE Healthcare).
Statistical analyses
Data obtained from colony growth assays were 
analyzed by Wilcoxon matched pair test. For other two 
group comparisons, two sample t-test or paired t-test were 
used depending on whether the data were dependent or 
independent. A p value of p < 0.05 was considered to be 
statistically significant. For all graphs, *p < 0.05, **p < 
0.01, ***p < 0.001, ****p < 0.0005, *****p < 0.0001.
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